NCT04656106

A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

A Retrospective Multi-centre Non-interventional Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: —

Summary

This is a non-interventional (observational), retrospective medical record review study collecting data reported in medical records of patients with T2D (Type 2 Diabetes ) who were treated with any basal-insulin or premix-insulin (plus/minus OAD (Oral Antidiabetic Drug)) for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg® (plus/minus OAD). All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Ryzodeg®	All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea. Hence independently of this study, the treating physician has determined the starting dose of Ryzodeg® as well as any dose adjustments thereafter.

Timeline

• Start date: 2021-04-27
• Primary completion: 2021-07-01
• Completion: 2021-07-01
• First posted: 2020-12-07
• Last updated: 2021-09-28

Locations

6 sites across 1 country: South Korea